JP2017537896A5 - - Google Patents

Download PDF

Info

Publication number
JP2017537896A5
JP2017537896A5 JP2017525022A JP2017525022A JP2017537896A5 JP 2017537896 A5 JP2017537896 A5 JP 2017537896A5 JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017525022 A JP2017525022 A JP 2017525022A JP 2017537896 A5 JP2017537896 A5 JP 2017537896A5
Authority
JP
Japan
Prior art keywords
hvr
amino acid
seq
acid sequence
region polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017525022A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017537896A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/075879 external-priority patent/WO2016075037A1/en
Publication of JP2017537896A publication Critical patent/JP2017537896A/ja
Publication of JP2017537896A5 publication Critical patent/JP2017537896A5/ja
Pending legal-status Critical Current

Links

JP2017525022A 2014-11-10 2015-11-06 二重特異性抗体及び眼科に使用する方法 Pending JP2017537896A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14192517.2 2014-11-10
EP14192517 2014-11-10
PCT/EP2015/075879 WO2016075037A1 (en) 2014-11-10 2015-11-06 Bispecific antibodies and methods of use in ophthalmology

Publications (2)

Publication Number Publication Date
JP2017537896A JP2017537896A (ja) 2017-12-21
JP2017537896A5 true JP2017537896A5 (enExample) 2018-12-06

Family

ID=51868112

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017525022A Pending JP2017537896A (ja) 2014-11-10 2015-11-06 二重特異性抗体及び眼科に使用する方法

Country Status (15)

Country Link
US (1) US10730938B2 (enExample)
EP (1) EP3218399A1 (enExample)
JP (1) JP2017537896A (enExample)
KR (1) KR20170080584A (enExample)
CN (1) CN107074941A (enExample)
AR (1) AR102592A1 (enExample)
AU (1) AU2015345323A1 (enExample)
BR (1) BR112017009764A2 (enExample)
CA (1) CA2963175A1 (enExample)
IL (1) IL251128A0 (enExample)
MX (1) MX2017005977A (enExample)
RU (1) RU2017120360A (enExample)
SG (1) SG11201703428SA (enExample)
TW (1) TW201632551A (enExample)
WO (1) WO2016075037A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2417156E (pt) 2009-04-07 2015-04-29 Roche Glycart Ag Anticorpos trivalentes, biespecíficos
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
WO2016075035A1 (en) * 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
EP3218400A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-pdgf-b antibodies and methods of use
WO2016087416A1 (en) 2014-12-03 2016-06-09 F. Hoffmann-La Roche Ag Multispecific antibodies
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
CN109863171B (zh) 2016-08-23 2023-08-04 免疫医疗有限公司 抗vegf-a和抗ang2抗体及其用途
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
WO2020127873A1 (en) * 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Antibody that binds to vegf and il-1beta and methods of use
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP7674383B2 (ja) * 2020-03-30 2025-05-09 エフ． ホフマン－ラ ロシュ アーゲー Ｖｅｇｆ及びｐｄｇｆ－ｂに結合する抗体及び使用方法
JP2024520693A (ja) * 2021-06-04 2024-05-24 イノベント バイオロジクス（スーチョウ）カンパニー，リミティド ＶＥＧＦとＡｎｇ２に結合する二重特異性結合分子およびその使用
CN116925234B (zh) * 2022-04-02 2024-05-31 合肥星眸生物科技有限公司 一种编码抗vegf-a和ang-2双特异性抗体的aav载体
CN117467025B (zh) * 2023-12-28 2024-04-16 上海鼎新基因科技有限公司 一种抗vegf和补体双功能融合蛋白及其应用
WO2025211874A1 (ko) * 2024-04-04 2025-10-09 주식회사 크로스포인트테라퓨틱스 인간 항체 fc 변이체 포함 이중항체 및 그 용도

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935343A (en) 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AU2003208946A1 (en) 2002-02-28 2003-09-16 Eli Lilly And Company Anti-interleukin-1 beta analogs
CN1678634A (zh) 2002-06-28 2005-10-05 多曼蒂斯有限公司 免疫球蛋白单个变体抗原结合区及其特异性构建体
JP4538461B2 (ja) 2003-01-24 2010-09-08 アプライド モレキュラー エボリューション，インコーポレイテッド ヒトＩＬ−１βアンタゴニスト
RU2346950C2 (ru) 2003-01-28 2009-02-20 Академис Зикенхейс Лейден Пептидные ингибиторы токсинов, производные ll-37
WO2005052002A2 (en) 2003-11-20 2005-06-09 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
ZA200705695B (en) 2004-12-21 2009-02-25 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
JP2008543839A (ja) 2005-06-14 2008-12-04 アムジェン インコーポレーテッド 自己緩衝タンパク質製剤
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
BRPI0811466A2 (pt) 2007-05-07 2014-10-14 Medimmune Llc Anticorpo anti-icos isolado, ácido nucleico, vetor, célula isolada, métodos para produzir um anticorpo, para tratar uma doença ou distúrbio, para tratar ou prevenir a rejeição em um paciente de transplante humano, para tratar uma malignidade de célula t em um ser humano, para esgotar células t que expressam icos em um paciente humano, para romper a arquitetura do centro germinal em um órgão linfóide secundário de um primata, para esgotar células b centrais germinais de órgão linfóide secundário de um primata, e para esgotar células b comutadas em classes circulantes em um primata, e, composição farmacêutica.
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
HRP20130042T1 (hr) 2008-06-06 2013-03-31 Xoma Technology Ltd. Postupci lijeäśenja reumatoidnog artritisa
RU2368359C1 (ru) 2008-07-22 2009-09-27 Государственное учреждение "УФИМСКИЙ НАУЧНО-ИССЛЕДОВАТЕЛЬСКИЙ ИНСТИТУТ ГЛАЗНЫХ БОЛЕЗНЕЙ" Академии наук Республики Башкортостан (УфНИИ ГБ АН РБ) Способ лечения возрастной макулярной дегенерации
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
NZ593905A (en) 2009-01-29 2013-03-28 Abbott Lab Il-1 binding proteins
AU2010306681A1 (en) 2009-10-15 2012-04-19 Abbvie Inc. IL-1 binding proteins
TW201138821A (en) 2010-03-26 2011-11-16 Roche Glycart Ag Bispecific antibodies
TWI426920B (zh) * 2010-03-26 2014-02-21 Hoffmann La Roche 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
BR112012028557A2 (pt) * 2010-05-07 2019-09-24 Xoma Technology Ltd. uso de um anticorpo anti-il-1b ou de fragmentos de ligação do mesmo.
CN104474546A (zh) 2010-08-13 2015-04-01 弗·哈夫曼-拉罗切有限公司 用于疾病治疗的针对IL-1β和IL-18的抗体
WO2012034039A2 (en) 2010-09-10 2012-03-15 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
MX2013007332A (es) 2010-12-21 2014-01-23 Abbvie Inc Inmunoglobulinas de dominio variable doble biespecificas de il-1 alfa y beta y su uso.
WO2012125850A1 (en) 2011-03-16 2012-09-20 Amgen Inc. Fc variants
EP2726088B1 (en) 2011-06-29 2019-01-02 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
SG11201408196RA (en) * 2012-06-28 2015-03-30 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
SI3495387T1 (sl) * 2012-07-13 2021-12-31 Roche Glycart Ag Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil
US20140093498A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf-r agents
WO2014049100A1 (en) 2012-09-28 2014-04-03 Boehringer Ingelheim International Gmbh Pharmaceutical combinations comprising dual angiopoietin-2 / dll4 binders and anti-vegf agents
AU2013342275B2 (en) 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
RU2015115956A (ru) * 2012-11-09 2017-01-10 Пфайзер Инк. Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
AU2014227732A1 (en) 2013-03-15 2015-09-17 Abbvie Inc. Dual specific binding proteins directed against IL-1 beta and IL-17
CA2904806C (en) * 2013-04-29 2021-11-23 F. Hoffmann-La Roche Ag Human fcrn-binding modified antibodies and methods of use
CN105611944A (zh) 2013-12-20 2016-05-25 豪夫迈·罗氏有限公司 抗ang2抗体和cd40激动剂的组合疗法
CN110903398B (zh) 2014-01-15 2023-08-15 豪夫迈·罗氏有限公司 具有修饰的FCRN和保持的蛋白A结合性质的Fc区变体
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP2017537896A (ja) 2014-11-10 2017-12-21 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二重特異性抗体及び眼科に使用する方法
EP3218400A1 (en) 2014-11-10 2017-09-20 F. Hoffmann-La Roche AG Anti-pdgf-b antibodies and methods of use
WO2016075035A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-ang2 antibodies and methods of use
SG11201702550WA (en) 2014-11-10 2017-04-27 Hoffmann La Roche ANTI-IL-1beta ANTIBODIES AND METHODS OF USE
WO2016209972A1 (en) 2015-06-26 2016-12-29 Amgen Inc. Biomarker of survival in the treatment of renal cell carcinoma with a vegfr inhibitor and an ang2 inhibitor
BR112019022074A2 (pt) 2017-06-02 2020-05-12 Boehringer Ingelheim International Gmbh Terapia de combinação anticâncer

Similar Documents

Publication Publication Date Title
RU2017120360A (ru) Биспецифические антитела и способы их применения в офтальмологии
JP2017534646A5 (enExample)
JP2017504566A5 (enExample)
JP2020062036A5 (enExample)
JP2017534645A5 (enExample)
HRP20211357T1 (hr) Bispecifična protutijela specifična za pd-1 i tim3
JP2017534644A5 (enExample)
HRP20200384T1 (hr) Humanizirana anti-tau(ps422) protutijela i načini uporabe
RU2019134338A (ru) Иммуноконъюгаты антитела к pd-1 с мутантом il-2 или с il-15
JP2018537966A5 (enExample)
HRP20241775T1 (hr) Bispecifična protutijela koja se specifično vežu na pd1 i lag3
JP2019501883A5 (enExample)
IL302486A (en) Antibodies against the transnephrine receptor with adapted affinity
HRP20211528T1 (hr) Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
JP2018522541A5 (enExample)
JP2019533441A5 (enExample)
FI3177643T5 (fi) T-soluja aktivoivia bispesifisiä antigeeniä sitovia molekyylejä
HRP20191766T1 (hr) Varijante fc regije s modificiranim vezanjem na neonatalni fc receptor (fcrn) i postupci primjene
HRP20191584T1 (hr) Anti-cd79b protutijela i načini uporabe
RU2016133347A (ru) Варианты fc-области с улучшенной способностью связываться с белком а
JP2024534545A5 (enExample)
JP2019502712A5 (enExample)
RU2016124325A (ru) Антитела к альфа-синуклеину и способы применения
RU2015145719A (ru) Модифицированные асимметричные антитела, связывающие fc-рецептор, и способы их применения
JP2017515811A5 (enExample)